Oruka Therapeutics (ORKA) Institutional Ownership
13F filers reported holding 6.5% of Oruka Therapeutics (ORKA) shares as of Sep 30, 2026, across 78 filers.
- Held by 13F filers
- 6.5%
- Sep 30, 2026
- 13F filers
- 78
- quarter ended Sep 30, 2026
- 13F value
- $360.9M
- 4.3M shares
- Quarter's fund flow
- Mild accumulation
- 15 new · 9 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | Acquired · Option exercise | 8,542 | $12.50 | ↗ |
| Nov 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | Acquired · Option exercise | 1,458 | $34.39 | ↗ |
| Nov 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | Disposed · Open-market sale | 500 | $101.98 | ↗ |
| Nov 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | Disposed · Open-market sale | 801 | $103.16 | ↗ |
| Nov 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | Disposed · Open-market sale | 799 | $104.25 | ↗ |
| Nov 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | Disposed · Open-market sale | 6,842 | $105.28 | ↗ |
| Nov 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | Disposed · Open-market sale | 958 | $106.18 | ↗ |
| Nov 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | Disposed · Open-market sale | 100 | $107.00 | ↗ |
| Nov 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | Disposed · Option exercise | 8,542Employee Stock Option (right to buy) | — | ↗ |
| Nov 12, 2026 | Agarwal Arjun | Senior Vice President, Finance | Disposed · Option exercise | 1,458Employee Stock Option (right to buy) | — | ↗ |
| Nov 12, 2026 | BALL KRISTINE M | director | Acquired · Option exercise | 18,000 | $6.84 | ↗ |
| Nov 12, 2026 | BALL KRISTINE M | director | Disposed · Open-market sale | 1,196 | $102.10 | ↗ |
| Nov 12, 2026 | BALL KRISTINE M | director | Disposed · Open-market sale | 1,300 | $103.09 | ↗ |
| Nov 12, 2026 | BALL KRISTINE M | director | Disposed · Open-market sale | 2,039 | $104.16 | ↗ |
| Nov 12, 2026 | BALL KRISTINE M | director | Disposed · Open-market sale | 10,765 | $105.31 | ↗ |
| Nov 12, 2026 | BALL KRISTINE M | director | Disposed · Open-market sale | 2,500 | $106.05 | ↗ |
| Nov 12, 2026 | BALL KRISTINE M | director | Disposed · Open-market sale | 200 | $106.99 | ↗ |
| Nov 12, 2026 | BALL KRISTINE M | director | Disposed · Option exercise | 18,000Stock Option (Right to Buy) | — | ↗ |
| Nov 2, 2026 | Klein Lawrence Otto | Chief Executive Officer | Acquired · Option exercise | 25,000 | $7.80 | ↗ |
| Nov 2, 2026 | Klein Lawrence Otto | Chief Executive Officer | Disposed · Open-market sale | 6,466 | $94.77 | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Oruka Therapeutics do institutions hold?
13F filers reported holding 6.5% of Oruka Therapeutics' shares as of Sep 30, 2026, across 78 filers.
How many 13F filers hold Oruka Therapeutics?
Oruka Therapeutics was held by 78 13F filers as of Sep 30, 2026.
Not investment advice.

